Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Er-Zhi-Wan (also known as Erzhi Pill or Two Solstices Pill) is a classic Traditional Chinese Medicine (TCM) formula consisting of two herbal ingredients: Nu Zhen Zi (Fructus Ligustri Lucidi) and Han Lian Cao (Herba Ecliptae), typically in a 1:1 ratio. Traditionally used to nourish liver and kidney yin, it is clinically investigated for various conditions including primary biliary cholangitis (PBC), osteoporosis, menopausal syndrome, and age-related muscle and bone loss. In a clinical trial sponsored by Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Er-Zhi-Wan is evaluated in combination with Shi-Xiao-San Powder and ursodeoxycholic acid (UDCA) for the treatment of stage II-III primary biliary cholangitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Er-Zhi-Wan (Longhua Hospital Shanghai University of Traditional Chinese Medicine).